181 related articles for article (PubMed ID: 26590443)
1. Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors.
Higuchi M; Suzuki H; Gotoh M
PET Clin; 2016 Jan; 11(1):47-55. PubMed ID: 26590443
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
3. The Maximum standardized uptake value is more reliable than size measurement in early follow-up to evaluate potential pulmonary malignancies following radiofrequency ablation.
Alafate A; Shinya T; Okumura Y; Sato S; Hiraki T; Ishii H; Gobara H; Kato K; Fujiwara T; Miyoshi S; Kaji M; Kanazawa S
Acta Med Okayama; 2013; 67(2):105-12. PubMed ID: 23603927
[TBL] [Abstract][Full Text] [Related]
4. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
Schoellnast H; Larson SM; Nehmeh SA; Carrasquillo JA; Thornton RH; Solomon SB
Cardiovasc Intervent Radiol; 2011 Feb; 34 Suppl 2():S182-5. PubMed ID: 20508937
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of pre-radiofrequency ablation SUV(max) in 18F-FDG PET/CT to predict the risk of a local recurrence of malignant lung tumors after lung radiofrequency ablation.
Harada S; Sato S; Suzuki E; Okumura Y; Hiraki T; Gobara H; Mimura H; Kanazawa S; Kaji M; Fujiwara T
Acta Med Okayama; 2011 Dec; 65(6):395-402. PubMed ID: 22189480
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.
Purandare NC; Rangarajan V; Shah SA; Sharma AR; Kulkarni SS; Kulkarni AV; Dua SG
Radiographics; 2011; 31(1):201-13. PubMed ID: 21257942
[TBL] [Abstract][Full Text] [Related]
8. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors.
Sharma A; Lanuti M; He W; Palmer EL; Shepard JA; Digumarthy SR
J Comput Assist Tomogr; 2013; 37(1):9-14. PubMed ID: 23321827
[TBL] [Abstract][Full Text] [Related]
9. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.
Higuchi M; Honjo H; Shigihara T; Shishido F; Suzuki H; Gotoh M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1957-63. PubMed ID: 24952227
[TBL] [Abstract][Full Text] [Related]
11. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.
Deandreis D; Leboulleux S; Dromain C; Auperin A; Coulot J; Lumbroso J; Deschamps F; Rao P; Schlumberger M; de Baère T
Radiology; 2011 Jan; 258(1):270-6. PubMed ID: 21045185
[TBL] [Abstract][Full Text] [Related]
12. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
13. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M
J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
Okuma T; Matsuoka T; Okamura T; Wada Y; Yamamoto A; Oyama Y; Koyama K; Nakamura K; Watanabe Y; Inoue Y
J Nucl Med; 2006 Aug; 47(8):1351-8. PubMed ID: 16883016
[TBL] [Abstract][Full Text] [Related]
15. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis.
Poulou LS; Ziakas PD; Ziogas DC; Doxani C; Xyla V; Vakrinos G; Voulgarelis M; Thanos L
Biomarkers; 2012 Sep; 17(6):532-8. PubMed ID: 22712479
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT in evaluation of radiofrequency ablation of liver metastasis.
Thulkar S; Chawla M; Sharma P; Malhotra A; Kumar R
Clin Nucl Med; 2012 May; 37(5):498-501. PubMed ID: 22475904
[TBL] [Abstract][Full Text] [Related]
18. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
Veit P; Antoch G; Stergar H; Bockisch A; Forsting M; Kuehl H
Eur Radiol; 2006 Jan; 16(1):80-7. PubMed ID: 15868122
[TBL] [Abstract][Full Text] [Related]
19. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
[TBL] [Abstract][Full Text] [Related]
20. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
